# A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

> **NCT02076009** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 569 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Daratumumab
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02076009
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-23
- **Primary completion:** 2016-03-07
- **Final completion:** 2024-11-21
- **Target enrollment:** 569 (ACTUAL)
- **Last updated:** 2025-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02076009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02076009, "A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02076009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*